Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine

Trial Profile

A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Galcanezumab (Primary)
  • Indications Migraine
  • Focus Adverse reactions
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 01 May 2020 Results (n=135) assessing changes from baseline in migraine-specific patient-reported outcomes (PRO) measures of patient functioning and disability in patients with migraine, presented at the 72nd Annual Meeting of the American Academy of Neurology.
    • 27 Apr 2020 Results to characterize the immunogenicity profile of galcanezumab across four phase 3 clinical trials (Evolve-1, Evolve-2, Regain, NCT01625988, NCT02163993 and NCT02614287) and CGAJ (NCT02614287) in which patients with episodic or chronic migraine were treated for up to 52 weeks published in the Cephalalgia
    • 12 Dec 2018 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top